Alpha-melanocyte stimulating hormone increases the activity of melanocortin-3 receptor-expressing neurons in the ventral tegmental area.
MC3R
VTA
dopamine
α-MSH
Journal
The Journal of physiology
ISSN: 1469-7793
Titre abrégé: J Physiol
Pays: England
ID NLM: 0266262
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
20
09
2018
accepted:
19
04
2019
pubmed:
6
5
2019
medline:
12
9
2020
entrez:
5
5
2019
Statut:
ppublish
Résumé
Alpha-melanocyte stimulating hormone (α-MSH) is an anorexigenic peptide. Injection of the α-MSH analog MTII into the ventral tegmental area (VTA) decreases food and sucrose intake and food reward. Melanocortin-3 receptors (MC3R) are highly expressed in the VTA, suggesting that the effects of intra-VTA α-MSH may be mediated by α-MSH changing the activity of MC3R-expressing VTA neurons. α-MSH increased the firing rate of MC3R VTA neurons in acute brain slices from mice, although it did not affect the firing rate of non-MC3R VTA neurons. The α-MSH induced increase in MC3R neuron firing rate is probably activity-dependent, and was independent of fast synaptic transmission and intracellular Ca The mesocorticolimbic dopamine system, the brain's reward system, regulates multiple behaviours, including food intake and food reward. There is substantial evidence that the melanocortin system of the hypothalamus, an important neural circuit controlling feeding and body weight, interacts with the mesocorticolimbic dopamine system to affect feeding, food reward and body weight. For example, melanocortin-3 receptors (MC3Rs) are expressed in the ventral tegmental area (VTA) and our laboratory previously showed that intra-VTA injection of the MC3R agonist, MTII, decreases home-cage food intake and operant responding for sucrose pellets. However, the cellular mechanisms underlying the effects of intra-VTA alpha-melanocyte stimulating hormone (α-MSH) on feeding and food reward are unknown. To determine how α-MSH acts in the VTA to affect feeding, we performed electrophysiological recordings in acute brain slices from mice expressing enhanced yellow fluorescent protein in MC3R neurons to test how α-MSH affects the activity of VTA MC3R neurons. α-MSH significantly increased the firing rate of VTA MC3R neurons without altering the activity of non-MC3R expressing VTA neurons. In addition, the α-MSH-induced increase in MC3R neuron activity was independent of fast synaptic transmission and intracellular Ca
Identifiants
pubmed: 31054267
doi: 10.1113/JP277193
pmc: PMC6666402
mid: NIHMS1028130
doi:
Substances chimiques
Receptor, Melanocortin, Type 3
0
alpha-MSH
581-05-5
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3217-3232Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK104999
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK020572
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK115503
Pays : United States
Informations de copyright
© 2019 The Authors. The Journal of Physiology © 2019 The Physiological Society.
Références
Nat Neurosci. 1998 Aug;1(4):271-2
pubmed: 10195157
Acta Physiol Scand. 1999 Oct;167(2):99-104
pubmed: 10571544
Psychopharmacology (Berl). 2000 Sep;152(1):67-73
pubmed: 11041317
Brain Res. 1975 Jan 17;83(3):531-7
pubmed: 1111820
Neuroreport. 2001 Jul 20;12(10):2155-8
pubmed: 11447325
Cell Mol Neurobiol. 2001 Oct;21(5):523-33
pubmed: 11860189
Diabetes. 2002 May;51(5):1337-45
pubmed: 11978628
Nature. 1976 Mar 18;260(5548):258-60
pubmed: 1256567
J Neurosci. 2003 Aug 6;23(18):7143-54
pubmed: 12904474
Science. 2004 Mar 26;303(5666):2040-2
pubmed: 15044807
Neurosci Lett. 2004 May 6;361(1-3):68-71
pubmed: 15135895
Nat Rev Neurosci. 2004 Jun;5(6):483-94
pubmed: 15152198
Neuron. 2004 Jun 24;42(6):939-46
pubmed: 15207238
Endocrinology. 2005 Mar;146(3):1043-7
pubmed: 15591135
Annu Rev Public Health. 2005;26:239-57
pubmed: 15760288
J Neurophysiol. 2006 Aug;96(2):535-43
pubmed: 16394077
J Neurosci. 2006 Mar 8;26(10):2788-97
pubmed: 16525058
Neuron. 2006 Sep 21;51(6):801-10
pubmed: 16982424
Endocrinology. 2007 Feb;148(2):638-46
pubmed: 17068131
Regul Pept. 2007 Mar 1;139(1-3):115-21
pubmed: 17188372
Eur J Neurosci. 2007 Jan;25(1):106-18
pubmed: 17241272
J Neurosci. 2007 Jun 27;27(26):7021-7
pubmed: 17596451
Trends Neurosci. 2007 Aug;30(8):375-81
pubmed: 17604133
Neuron. 2008 Mar 13;57(5):760-73
pubmed: 18341995
Neuroscience. 2008 Apr 9;152(4):1024-31
pubmed: 18355970
J Neurosci. 2008 Oct 22;28(43):10905-17
pubmed: 18945898
J Nutr. 2009 Mar;139(3):629-32
pubmed: 19176746
Naunyn Schmiedebergs Arch Pharmacol. 1977 Mar;297(1):1-7
pubmed: 193046
Am J Clin Nutr. 2009 Dec;90(6):1453-6
pubmed: 19828708
J Neurochem. 1991 Mar;56(3):961-7
pubmed: 1993900
PLoS One. 2009 Nov 25;4(11):e7940
pubmed: 19946359
Neurochem Int. 1986;9(1):85-9
pubmed: 20493104
J Neurosci. 2010 May 26;30(21):7401-13
pubmed: 20505107
Trends Cogn Sci. 2011 Jan;15(1):37-46
pubmed: 21109477
Nat Neurosci. 2011 Mar;14(3):351-5
pubmed: 21209617
Neuron. 2011 Feb 24;69(4):664-79
pubmed: 21338878
J Clin Invest. 2011 Apr;121(4):1424-8
pubmed: 21364278
J Physiol. 2011 Aug 1;589(Pt 15):3775-87
pubmed: 21646409
Lancet. 2011 Aug 27;378(9793):804-14
pubmed: 21872749
PLoS One. 2011;6(10):e25864
pubmed: 21991375
Nat Neurosci. 2012 Jun 24;15(8):1108-10
pubmed: 22729177
PLoS One. 2012;7(7):e42365
pubmed: 22860119
Psychopharmacology (Berl). 2013 Mar;226(1):25-34
pubmed: 23010797
Biol Psychiatry. 2013 May 1;73(9):860-8
pubmed: 23305991
Nat Neurosci. 2013 Mar;16(3):300-8
pubmed: 23354329
J Neurosci. 2013 Feb 20;33(8):3624-32
pubmed: 23426689
Endocrinology. 2014 Mar;155(3):840-53
pubmed: 24424063
J Physiol. 1987 Nov;392:397-416
pubmed: 2451725
Endocrinology. 2014 May;155(5):1718-27
pubmed: 24605830
Psychopharmacology (Berl). 2015 Jan;232(1):285-94
pubmed: 24985892
Neuroscience. 2014 Dec 12;282:109-21
pubmed: 25073045
Neuroscience. 2015 Mar 19;289:19-42
pubmed: 25583635
J Physiol. 2015 Jun 15;593(12):2547-9
pubmed: 26095019
Neurosci Biobehav Rev. 2015 Sep;56:15-25
pubmed: 26116876
J Neurophysiol. 2015 Sep;114(3):1734-45
pubmed: 26180119
Neuropsychopharmacology. 2016 Aug;41(9):2241-51
pubmed: 26852738
Nat Rev Neurosci. 2017 Feb;18(2):73-85
pubmed: 28053327
Cell Rep. 2017 Feb 7;18(6):1346-1355
pubmed: 28178514
Psychopharmacology (Berl). 2017 Jun;234(11):1683-1692
pubmed: 28243712
Life Sci. 1988;42(17):1651-7
pubmed: 2835562
J Neurophysiol. 2017 Jul 1;118(1):625-633
pubmed: 28469002
N Engl J Med. 2017 Jul 6;377(1):13-27
pubmed: 28604169
Annu Rev Physiol. 2018 Feb 10;80:219-241
pubmed: 28938084
Psychopharmacology (Berl). 1987;92(3):343-9
pubmed: 2957718
Endocrinology. 2019 Feb 1;160(2):343-358
pubmed: 30541071
Pharmacol Biochem Behav. 1986 Dec;25(6):1149-51
pubmed: 3809216
J Neurosci. 1984 Nov;4(11):2866-76
pubmed: 6150070
J Neurosci. 1984 Nov;4(11):2877-90
pubmed: 6150071
Psychopharmacology (Berl). 1994 Dec;116(4):529-37
pubmed: 7701059
Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8856-60
pubmed: 8415620
Cell. 1995 Dec 29;83(7):1197-209
pubmed: 8548806
Nature. 1997 Jan 9;385(6612):165-8
pubmed: 8990120
J Neurophysiol. 1997 Feb;77(2):853-62
pubmed: 9065854
Neuroscience. 1997 Jul;79(2):323-7
pubmed: 9200717
Science. 1997 Oct 3;278(5335):135-8
pubmed: 9311920